| Authors: |
Hayes DF; University of Michigan Rogel Cancer Center, Ann Arbor, MI., Herbst RS; Yale University, New Haven, CT., Myles JL; The Cleveland Clinic, Cleveland, OH., Topalian SL; Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD., Yohe SL; University of Minnesota, Minneapolis, MN., Aronson N; Blue Cross Blue Shield Association, Chicago, IL., Bellizzi AM; University of Iowa, Iowa City, IA., Basu Roy U; LUNGevity Foundation, Chicago, IL., Bradshaw G; The College of American Pathologists, Northfield, IL., Edwards RH; Bristol-Myers Squibb, New York, NY (at time of summit).; Daiichi Sankyo Inc, Baskin Ridge, NJ., El-Gabry EA; Roche Tissue Diagnostics, Indianapolis, IN.; Akoya Biosciences, Marlborough, MA., Elvin J; Foundation Medicine, Beverly, MA., Gajewski TF; University of Chicago, Chicago, IL., McShane LM; National Institutes of Health/National Cancer Institute, Bethesda, MD., Oberley M; Caris Life Sciences, Phoenix, AZ., Philip R; United States Food and Drug Administration, Silver Spring, MD., Rimm DL; Yale University, New Haven, CT., Rosenbaum JN; Kaiser Permanente Northern California Regional Genetics Laboratory, San Jose, CA., Rubin EH; Merck & Co Inc, Kenilworth, NJ., Schlager L; FORCE: Facing Our Risk of Cancer Empowered, Tampa, FL., Sherwood SW; American Society of Clinical Oncology, Alexandria, VA., Stewart M; Friends of Cancer Research, Washington, DC., Taube JM; Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD., Thurin M; National Institutes of Health/National Cancer Institute, Bethesda, MD., Vasalos P; The College of American Pathologists, Northfield, IL., Laser J; Everly Health, Austin, TX. |
